CSE: PREV OTCQB: PRVCF FSE: 18H - Proactiveinvestors UK€¦ · investor deck cse: prev otcqb: prvcf fse: 18h september 14, 2017

WWW.PREVECEUTICAL.COM

INVESTORDECK

CSE:PREVOTCQB:PRVCFFSE:18H

SEPTEMBER14,2017

2

DISCLAIMER

Thispresentationanditsappendices(togetherthe“Presentation”)havebeenpreparedanddeliveredbyPreveCeutical™MedicalInc. (“PreveCeutical”orthe“Company”)(CSE:PREV,FSE:18H).ThePresentationanditscontentsarestrictlyconfidentialandmaynotbereproducedorredistributed,inwholeorinpart,toanyotherpersonthantheintendedrecipientwithouttheCompany’swrittenconsent.

ThePresentationispreparedfordiscussionandinformationalpurposesonly.ThePresentationdoesnotconstitute,andshould notbeconstruedas,anyofferorinvitationorrecommendationtobuyorsellanyofthesecuritiesissuedbytheCompanyanddoesandwillnotconstituteorform orbepartofanyofferingmaterial.ThisPresentationisnotmeantforandshouldnotbedistributedtoU.S.Persons(asdefinedinRegulationSofthe UnitedStatesSecuritiesActof1933,asamended)orotherwisedistributedintheUnitedStatesofAmerica.

ThePresentationcontainsinformationwhichhasbeensourcedfromthirdpartiesbelievedtobereliable,butwithoutindependent verificationbytheCompany,itsboardofdirectors,management,employees,consultants,agents,oraffiliates.ThePresentationcontainscertainforward-lookingstatementsrelatingtothepotentialbusiness,financialperformanceandresultsoftheCompanyand/orindustriesandmarketsinwhichitisormayoperate within,includingforward-lookingforecasts.Thesestatementsmaycontainwordssuchas“will”,“expects”,“anticipates”,“believes”,“estimates”andwordsofsimilarimport.Anyforward-lookingstatementsandotherinformationcontainedinthisPresentation,includingassumptions,opinions,forecastsandviews,includingthosecitedfromthirdpartysources,aresolelyopinionsandforecastswhicharesubjecttorisks,uncertaintiesandotherfactorsthatmaycauseactualeventstodiffermateriallyfromanyanticipateddevelopment.Assuchbythenatureofanyforward-lookingstatement,relyingonsuchstatementsinvolvesrisk.

ThisPresentationhasnotbeenreviewedorregisteredwithanypublicauthority,stockexchangeorregulatedmarketplace.

Byattending/reviewing/readingorreceivingthisPresentationyouacknowledgethatyouwillbesolelyresponsibleforyourownassessmentoftheinformationherein,andthemarketandthemarketpositionoftheCompanyandthatyouwillconductyourownanalysisandbesolelyresponsibleforformingyourownviewofthepotentialfutureperformanceoftheCompanyoranypotentialfutureinvestmentintheCompany.NeithertheCompany,itsmanagementorboardofdirectors,noranysubsidiaryoftheCompanyoranysuchperson’sboardofdirectors,managementoraffiliatesmakesanyundertaking,representationorwarranty(expressorimplied)astotheaccuracyorcompletenessoftheinformation(whetherwrittenororalandwhetherornotincludedinthisPresentationincludingrelatedtoanymaterialsreferredtoorotherwiseincorporatedbyreferenceherein)concerningthemattersdescribedherein.NeithertheCompanynoranysubsidiaryoftheCompanyoranysuchperson’sboardofdirectors,management,employees,consultants,agents,oraffiliates acceptsanyliabilitywhatsoeverastoanyerrors,omissionsormisstatementscontainedhereinand,accordingly,neithertheCompanynoranysubsidiaryoftheCompanyoranysuchperson’saffiliates,agents,officers,directors,employees,andconsultantsacceptsanyliabilitywhatsoeverarisingdirectlyorindirectlyfromtheuseofthisPresentationortheinformationincludedherein.

ThePresentationspeaksandreflectsprevailingconditionsandviewsasofthedatedenotedonthecoverpage.Itmaybesubject tocorrectionsandchangeatanytimewithoutnotice.NeithertheCompanynoranysubsidiaryoftheCompanyoranysuchperson’sboardofdirectors,management,employees,consultants,agents,oraffiliatesintendsto,andneitherthedeliveryofthisPresentationnoranyfurtherdiscussionswithanyrecipientshall,underanycircumstances,createanyimplicationthattheCompanyoranyoftheaforementionedpartiesassumesanyobligationtoupdateorcorrecttheinformationhereinunlessrequiredbyapplicablelaw.TheinformationinthisPresentationiscurrentasofthedateofthisPresentationnotedonitsfirstpage,and readersareencouragedtoreviewtheCompany’spublicfilingsonitsSEDARprofileon www.sedar.com.

CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM

PreveCeuticalMedicalInc.,ledbyanexperiencedteamofseniorexecutivesandscientists,believesthemedicalcommunityistransitioningfromasystemwhich“fixedpeopleaftertheybecomeill”tooneofprecision,preventivebased,medicine.

Withthisfocus,PreveCeutical iscommittedtobecomealeaderinpreventivehealthsciences.

3

WHATWEBELIEVE


2016 2017 2018 2019

4

CurrentResearch&DevelopmentPrograms

Research&DevelopmentPartner

CurrentHomeopathicMedicines&Supplements

Natural&SyntheticPeptidesderivedfromBlueScorpion Venom.

Dualgene therapyforDiabetes &Obesity

What’snext?

Sol-gelplatformfortime-released,nose-to-braindeliveryofCBDs.

Pre-clinicalupfrontlicensingagreements.

What’snext?• Internationaldistribution

agreements• Productextensions• Marketingpartnerships

CELLB9®• Developed• Trademarked

DigitalMarketingprogramcommences.

TherapeuticProductJointVenture

WHATWEAREUPTO


R&DPROGRAMSATAGLANCE

5

PEPTIDERESEARCHPROGRAM• Identificationofpeptides• Synthesisandstabilization

SOL-GELDELIVERYPLATFORM• Analysisofplant-derivedCBDs• FormulationofCBDinfused

soluble-gels• Performdeliverystudies

DUALGENETHERAPY• Rationaldesignoftissuetargeted

bio-responsivegenedeliverysystems• Systematicevaluationtowardsgene

andproteinsilencinginappropriatemodels–multiplephasesCurativetherapyfordiabetes&obesity

2017 2018 2019 2020

PartneredResearchandDevelopmentprogramswithUniQuest,themaincommercialisationcompanyfortheUniversityofQueensland.Undertheagreements,intellectualpropertyarisingfromthecarryingoutof,resultsdevelopedduring,orcreatedbytheprogramswillbeownedbyPreveCeutical.

*Collaborators:QIMRBerghofer– ProfessorGrantRammandMurdochUniversity– Dr RakeshVeedu.


ResearchandDevelopmentProgramsTimeline

PEERCOMPARISONS

6CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM

COMPANYVALUATIONS&PIPELINES

SmallMolecule/Peptides

DrugDeliveryCBDs

GeneTherapy

PRE-CLINICAL PHASEI PHASEII PHASEIII NDA

Genmab

AximBiotech

GWPharmaceuticals

Novartis

Drug:MedChew-1401 (Chewinggum)•ProposedIndication:MultipleSchlerosis/PainSpasticity2

MarketCap:USD14Billion1SharePrice:USD$2351CPH:GEN

MarketCap:USD332Million2SharePrice:USD$6.332OTCQB:AXIM

MarketCap:USD2.7Billion5SharePrice:USD$107.095NASDAQ:GWPH

MarketCap:USD224Billion6SharePrice:USD$85.706NYSE:NVS

DrugName:Tisotumab vedotin (HuMax®-TF-ADC)•ProposedIndication:solidtumours (ovary,cervix,endometrium,bladder,prostate,head&neck,esophagus,lung1

Drug:GWP42006(CBDV)•ProposedIndication:Epilepsy3

Drug:CTL019(Tisagenlecleucel – chimericantigenreceptor-T”CAR-T”)•Indication:Relapsed/RefractoryB-cellacutelymphoblasticleukemia4

COMPANY/INDUSTRY

1 http://www.genmab.com/- SharePriceDate– September08,20172http://aximbiotech.com - SharePriceDate- September08,20173https://www.gwpharm.com/products-pipeline5http://www.nasdaq.com/symbol/gwph - SharePriceDate- September08,20174http://www.ajmc.com/newsroom/novartis-car-t-therapy-ctl019-approved-10-0-by-fdas-odac6 https://www.google.com/finance?q=NYSE:NVS- SharePriceDate– September08,2017

7

DevelopingnatureidenticaldrugsderivedfromBlueScorpion Venomthattreat,regulateandpreventcancerprogression.Precisiontreatmentsforearlystagetumorsandmetastaticlesions.

Theglobalmarketforcancertreatments$107Bnin 20151Projections– $161.30Bn by2021. 2

Dual-gene therapyfordiabetesandobesity.Proofofconcepthasalreadybeendemonstrated –based on5yearsofresearch,targetinga singlediabetesandobesitycausinggene.

2016globalexpenditureforDiabetesUSD$825Bn. 5Globaltype2diabetesmarketsettoreach$58.7 Bn. 6

DrugdeliverytechnologymarketUSD$1,669.40Bnby2021. 3GlobalneuropathicpainmarketUSD$8.3Bnby2024. 4

Sol-gel nose-to-brain deliverysystem,forCBDs,toprovideclinicalreliefacrossarange ofindicationsfrompain,inflammation,seizuresandneurologicaldisorders.

MEETINGCURRENTUNMETNEEDS

MARKETOPPORTUNITIES


1http://www.imshealth.com/en/about-us/news/ims-health-study-global-market-for-cancer-treatments-grows-to-107-billion-in-2015-fueled-by-record-level-of-innovation2https://globenewswire.com/news-release/2017/07/03/1037328/0/en/Global-Cancer-Drugs-Market-Size-Share-Will-Grow-USD-161-30-Billion-by-2021-Zion-Market-Research.html3http://www.marketsandmarkets.com/PressReleases/drug-delivery-technologies.asp4http://www.prnewswire.com/news-releases/global-neuropathic-pain-market-to-reach-us-83-bn-by-2024-end-developing-economies-expected-to-fuel-revenue-growth-603764096.html5https://www.hsph.harvard.edu/news/press-releases/diabetes-cost-825-billion-a-year/6http://www.drug-dev.com/Main/Back-Issues/Global-Type-2-Diabetes-Market-Set-to-Almost-Double-1140.aspx

8

Ourpre-clinicalprogramsareledbyDr.MakJawadekar (CSO),having28years’experiencewithPfizerInc., mostrecentlyasPfizer’sDirectorof PortfolioManagement.Dr. Jawadekar’sexperiencewithexternalpartnershipsandalliancesforresearchanddrugdevelopmentwillbeintrumentalforallofourResearchPrograms.

Mak JawadekarPh.D.- ChiefScienceOfficer

Specialties:R&D,ExternalAllianceManagement,Contracting,Outsourcing,Benchmarking,DrugDeliverySystemsassessment,Formulations,ClinicalSupplyMfg andPackaging,CTM,Pharmaceutics,PharmSciences,PerformanceMetricsevaluationsandassessment,AsiaR&D,ExtensiveNetworksintheUS,EU,IndiaandotherpartsofAsiaincludingJapanandChina.

RESEARCHTEAM


Dr.Harendra (Harry)Parekh,Ph.D,BSc.HonsI– ChiefResearchOfficer

BasedattheUniversityofQueensland’s(UQ)PharmacyAustraliaCentreofExcellence(PACE),Dr ParekhalsoholdsadjunctpositionsattheNationalUniversityofSingapore,andManipal University,India.Dr ParekhheadstheDrug/GeneDeliveryGroupatPACE-UQwithhisteamdevelopinghighlyinnovativeandtranslationalmedicinedeliverysystemsin-conjunctionwithphysicianswhoseexpertisespancancer,diabetes-&-obesity,maculardisease,infectiousdiseaseandtraditional(Chinese)medicine.

9

RESEARCHTEAM


Dr.RakeshVeedu isleadingthePrecisionNucleicAcidTheranostics group,asaMcCuskerResearchFellowwiththePerron InstituteforNeurologicalandTranslationalScience,basedatthe andCentreforComparativeGenomicsatMurdochUniversity(Perth,Australia).He,isanemergingexpert,nationallyandinternationally,inthefieldofmolecularmedicine.Heisusingnucleicacid-basedbiotechnologiesanddevelopingnovelnucleicacidaspotentialdrugtherapiesforarangeofneurologicaldiseases,geneticdisordersandsolidcancers.

ProfessorGrantRamm iscurrently theheadoftheHepaticFibrosisLaboratoryandCoordinatoroftheCellandMolecularBiologyDepartmentatQIMR-Berghofer,a leadingmedicalresearchinstitutelocatedin Brisbane,Australia.

10

RESEARCHCOLLABORATORS


11

PreveCeutical’s scientistswillusepropietary chemistrytogenerateNatureIdentical™peptides,consistingofalibraryofmodifiedpeptideanalogues,whichwillthenbetestedindiseasemodels.

Currentlyunderway,phaseone(ofthreedistinctphases)tofirstidentifyscorpionvenom-basedpeptides/proteins.

TheCaribbeanBlueScorpion(Rhopalurus junceus)venomisextremelyrichinavarietyofproteins,whichabnormalcellsconsume.Abnormalcellsemitauniqueelectrostaticchargethatattractstheproteininthevenom.

NATUREIDENTICAL™PEPTIDERESEARCHPROGRAM


§ Developingnatureidenticaltherapiesderivedfrom,naturalcompounds,startingwithBlueScorpionVenom,totreat,regulateandpreventcancerprogression.

§ Retainkeybeneficialproperties,soreplicatingthesynergiesthatnaturebringsallowingforconsistencyandefficacyinmassproduction.

§ One-stepsynthesis.

§ Effectivelymanufactureasmuchoftheproductasthemarketdemands.

PEPTIDER&DPROGRAM

12

Peptidesarecurrentlybeingusedtotargetanarrayofdiseaseindicationsincludingmetabolicdisorders,pain,cancers,cardiovascularandinfectiousdiseases.Thetherapeuticpeptidemarketisexpectedtoundergoanexpansionintheforeseeablefuture.

ThePeptideResearchandDevelopment(“R&D”)involvespeptidelibrarysynthesis,pharmacologicalevaluation,alongsidepharmacokineticassessmentandefficacydeterminationsinappropriateanimalmodelsofpainandinflammation.Thismayencompasseitherparty’sintellectualpropertyandproductlineandotherpharmaceuticalofferingsthatmayfallwithinthepeptideR&Dprogram.

AteamledbyDr.Parekhin-conjunctionwithfellowcollaboratorsatTheUniversityofQueensland(UQ)proposetoexpandtheuseoftheirdisulfidelinkertechnologytodevelopnon-addictiveanalgesicsformoderate-to-severepain.

PreveCeutical andUniQuest arecurrentlynegotiatingandpreparingthedefinitiveagreementregardingthecollaboration.

NON-ADDICTIVEANALGESICS


13

Developingthefirstnose-to-braindeliverysystemofCannabinoids(CBDs)

§ Provideclinicalreliefacrossarangeofindicationsfrompain,inflammation,seizuresandneurologicaldisorders.

§ Proprietaryformulationintendedfordeliveryviaanasalspray.

§ Extendedreleaseusingnanobubble technologytoallownormallife-style.

§ Universally-patientfriendly,meaningformulationsthatcanbeusedinchildrenandadultsalike.

Patentability

§ Anovelprocessforpreparinginsolubledrug-containingnanomicellesandtheirsuccessfulincorporationintosol-gelshasbeendevelopedintheParekhgroupatPACE-UQ.

§ Uniquest,UQ’stechtransfercompany,reviewedalldatainlate-Feb2017.ThePatentReviewCommitteeapprovedthefilingofaprovisionalpatentapplicationaroundthesinglephasesol-gelsfornasaldelivery.

SOL-GELDELIVERYPLATFORM


14

PreveCeutical isworkingwithfourleadingAustralianresearchcenterstoco-developapotentialcurefordiabetes&obesity.

DUALGENETHERAPYFORDIABETES&OBESITY


15

PreveCeutical iscommencingground-breakingresearchtargetingagenetherapy“curefortype-2diabetesandobesity.”BytakingagenesilencingapproachbyselectivelytargetingthegenethatencodesfortheproteinPTP-1B,reducingPTB-1Bproteinlevels,therebyreducingcapacitytostorefat,reversingobesity,fattyliverdiseaseetc.

Engineerapanelofnovel,ligand-targetedbio-responsivegenecarrier-&-releasesystems.

Re-synthesizeapanelofSmart-siRNAconstructingagainstthegeneimplicatedandover-expressedinbothtype-2diabetesandobesity

EvaluatesiRNA-bioresponsive carriercomplexesingeneandproteintargetingusingin-housederivedcellularmodelsofdiabetesandobesity,includingtoxicitystudies

Performbiodistribution studiesofleadsiRNA-carriercomplexesfocusingontheliver,skeletalmuscle,fatandbrainofhealthymice.

Performgene-proteinsilencingefficacyandsafetyevaluationstudiesinobese-diabeticandlean-diabeticmicewithourleadSmart-siRNAbio-responsivecarriersystems.

ABOUTTHEGENETHERAPYDEVELOPMENTPROGRAM

2017 2018 2019 2020


16

KILLSONEPERSONEVERYSIXSECONDS12015GLOBALEXPENDITUREUSD$673Bn 2040PROJECTIONSUSD$802Bn1LOSSESINGDPWORLDWIDEFROM2011– 2030USD$1.7TRILLION2

2http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf

Estimatednumberofpeoplewithdiabetesworldwideandperregionin2015and2040(20-79years)1

NorthAmericaandCaribbean1201544.3million204060.5million

Europe1

201559.8million204071.1million

FACTS&FIGURES


DIABETES:

1http://www.diabetesatlas.org/

MiddleEastandNorthAfrica1


Africa1


SouthEastAsia1


WesternPacific12015153.2million2040214.8million

SouthandCentralAmerica1


• Currentlyprescribedantidiabeticdrugtherapiesuniversallyaimtoreducebloodglucoselevelsbytargetingoneormoreofthesixkeyorgans/tissues,i.e.thepancreas,liver,skeletalmuscle,smallintestine,kidneys,andfatty tissue.

• AllofthecurrentlyavailableagentsusedtomanagediabeteshaveshownNOcapacitytohalttheprogressivedeclineofpancreaticβ-cellfunction– thecellsthatgenerates insulin!

• Conventionalagentsarealsolimitedbytheirunacceptablesideeffectsandadversesafetyprofile.

• AttemptstoBLOCKtheproteinusingconventionaldrugshasfailedduetoanarrayofunacceptablesideeffectsandsafetyissues.SeeChemicalReviewsarticle:http://pubs.acs.org/doi/abs/10.1021/cr5002832

17

• Ourdualgenetherapyapproachtargetsakeyprotein(PTP-1B)implicatedandover-producedbythekeyinsulinsensitiveorgansindiabetesandobesity– liver,fattytissue,skeletalmuscleandthebrain.

• OurgenesilencingapproachwouldselectivelytargetthegenethatencodesfortheproteinPTP-1BONLY,itisHIGHLYselective.

• ByreducingPTP-1Bproteinlevels,cellsinthekeyorganswouldhavereducedcapacitytostorefat,reversingobesity,fattyliverdisease,etc.

• ByreducingPTP-1Bproteinlevels,cellsignalingpathwaysthatpromoteglucoseuptakewouldbere-activatedandinsulinresistanceovercome.

CURRENTDRUGTHERAPIESVS.GENETHERAPY


DIABETES:

18

AIM5:

AIM2:

AIM3:

AIM4:

AIM1:

Themulti-disciplinaryteamhavemappedthenextphaseoftheproject,whichspans4years,andencompasses5keyaims.

Engineerapanelofnovel,ligand-targeted(i.e.liver,skeletalmuscle,fattytissueandbrain)bio-responsivegenecarrier-and-releasesystems.

Re-synthesizeapanelofSmart-siRNAconstructsagainstthegeneimplicatedandover-expressedinbothtype-2diabetesandobesity.

EvaluatesiRNA-bioresponsive carriercomplexesingeneandproteintargetingusingin-housederivedcellularmodelsofdiabetesandobesity,includingtoxicitystudies.

Performbiodistribution studiesofleadsiRNA-carriercomplexesfocusingonliver,skeletalmuscle,fattytissueandbrainofhealthymice.

Performgene-proteinsilencingefficacyandsafetyevaluationstudiesinobese-diabeticandlean-diabeticmicewithourSmart-siRNAbio-responsivecarriersystems.

TOPRECLINICALEVALUATION


THENEXTPHASETHROUGH

19

WARRENMOON- PRESIDENT DAVIDMELTZER- CEO

JOINTVENTUREWITHSPORTS1 MARKETING


JointVentureestablishedtodevelopatherapeuticproductsgearedtowardsathleteswhosufferfromconcussions(MildTraumaticBrianInjuryorTBI).

PreveCeutical andSports1MarketingbelievethatthereistherapeuticpotentialinthepeptidesandproteinsconnectedtotheCaribbeanBlueScorpionvenomtopotentiallytreatconcussions.

• 2010’sestimatedeconomiccostsofconcussionsis$76.5Bn,ofthis,90%arefatalconcussions. 1

• Hundredsofthousandsofheadtraumas,includingundiagnosedconcussionsgounreportedanduntreatedeachyear. 2

• Undiagnosedbraininjuriesareamajorcauseof depression, anxiety,drug,alcoholabuse,homelessness, ADD/ADHD andsuicide. 2

2AmenClinics;http://www.amenclinics.com/conditions/brain-injury/1CentersforDiseaseControlandPrevention;https://www.cdc.gov/TraumaticBrainInjury/index.html

THERAPEUTICPRODUCT- TBI

20

StephenVanDeventer - Chairman&ChiefExecutiveOfficer

Mr.VanDeventerisanexperiencedbusinessmanandcorporatedirector.Specializingininternationalcorporaterelationsandbusinessdevelopmentoverthelasttwentyfiveyears,Mr.VanDeventerhasfocusedonlaunchingsmalltomediumsizedcompaniesintothepublicmarketsinCanada,theUnitedStatesandEurope.Hehasalsoownedandoperatedprivatecompanies.

KimberlyVanDeventer- President&Director

Ms.VanDeventerisanentrepreneurwithasuccessfultrackrecordofaccomplishmentthatshebringstoPreveCeutical.Motivatedanddetermined,shewasrankedthethirdhighestgrossingfemalebusinessownerinBC,Canadain2009.Kimisadrivingforcebehindthebusinessandisunwaveringinhercommitmenttobringawarenessofhealthanddiseasepreventiontopeople everywhere.

BrianHarris- V.P.CorporateDevelopment&Director

Mr.HarrisisManagingPartneratMarketingServicesInternational.BrianHarrisservedasaDirectorandCEOofRussellBreweriesInc.,aTSX-VlistedCompany.Duringhistenyeartenure,RussellwasoneofthefastestgrowingcompaniesinCanada.PriortothathewasaDirectorandSVPforEFTechLtd.,apubliccompanylistedontheASXandaleadingsupplierofElectronicFundsTransferservicesinAustralia.AfounderofBASS(BestAvailableSeatingService)International,thecomputerticketingsystemwhichoperatedin12marketsand4continentsnowknownas TicketMaster.

LEADERSHIPTEAM


21

ShabiraRajan,MBA,CPA,CGA - ChiefFinancialOfficer&Controller

Ms.Rajanisaseniorfinancialexecutivewithover20yearsofexperience,leadingthefinancialdisciplineforsuccessfulbusinessesinbothprivateandpublicsectors.Shehasatrackrecordofprovidingleadershipforstrategicvaluecreationandcontinuousimprovement,aswellas,providingeffectivedirectionto organizationsonissuesrelatingtocorporategovernance,financialoversightandriskmanagement.Oneofherleadershiproleswasthatof DirectorofFinanceatCanadaLineRapidTransitInc.,whichplanned and constructed a $2billion rapid transit system inmetro-Vancouver, on time andwithin budget.

GregS.Reid-Director

FilmmakerandKeynoteSpeakerGregS.Reidisa#1best-sellingauthor,entrepreneur,andtheCEOofseveralsuccessfulcorporations,whohasdedicatedhislifetohelpingothersachievetheultimatefulfillmentoffindingandlivingalifeofpurpose.Inadditiontobeingpublishedinover35booksandfeaturedonNationallySyndicatedprogramsacrosstheU.S.,heisalsothecreatorandproducerontheInternationalacclaimedfilmsPassItOn,andThreeFeetFromGold.*(ListedonIMDB)

MattColtura-Director

Mr.Coltura isinthefinalyearoftheBBA,withfinanceoption,atOkanaganCollege.Hehasbeeninthefinanceindustryfor3years.Currently,Mr.Coltura istheCFOofCayenneCapitalCorpandsitsontheboardofdirectorsforStoneridgeExplorationandCarreraExploration.

LEADERSHIPTEAM


22

MakJawadekarPh.D.- ChiefScienceOfficer

Dr.MakJawadekarworkedatPfizerInc.inGroton-NewLondon,Connecticut,for28consecutiveyearsmorerecentlyasaDirectorofPortfolioManagement.HewasresponsibleforDrugDeliveryTechnologyAssessmentfunctioninvolvingexternal‘DrugDelivery’technologies.Hehasextensiveexperienceincreatingandcultivatingexternalpartnershipsandalliancesfordrugdeliverytechnologies.HebeganhisprofessionalcareeratPfizerCentralResearchinearly1982,afterhavingcompletedhisPh.D.inPharmaceuticsattheUniversityofMinnesota.

HarryParekh.Ph.D,BScHonsI - ChiefResearchOfficer

BasedattheUniversityofQueensland’s(UQ)PharmacyAustraliaCentreofExcellence(PACE),DrParekhalsoholdsadjunctpositionsattheNationalUniversityofSingapore,andManipal University,India.Dr ParekhheadstheDrug/GeneDeliveryGroupatPACE-UQwithhisteamdevelopinghighlyinnovativeandtranslationalmedicinedeliverysystemsin-conjunctionwithphysicianswhose expertisespancancer,obesity-&-diabetes,maculardisease,infectiousdiseaseandtraditional(Chinese)medicine.

NicoleGoncalves-Krysinski - ChiefLegalOfficer

NicoleGoncalves-Krysinski,Esq.,isanattorneyandapartnerinherownlawfirminNewYorkCity,NewYork.ShehasatJ.D.fromSt.John’sUniversityandB.A.fromU.C.L.A.Nicolepracticesinbothstateandfederalcourtshandlingawiderangeofcasesincludingcomplexbankruptcymatters,matrimonialandcriminaldefenselitigation.Herareasofpracticealsoincludecontractnegotiations,businessandtransactionallawandcorporate advisement.

LEADERSHIPTEAM


23

AliciaRebman– VPMarketing&Advertising

Ms.RebmanisaMarketingprofessionalwithabackgroundinPublishingTechnologies,CommunicationsandGraphicDesign;specialtyinbranding&communicationsforsocialenterpriseandNGOstart-ups.Ms.Rebmanranasuccessfuldesignservicescompanyfor6yearsandthenelevatedtoheadthemarketingdepartmentfortheGlobalofficeofHartley&MarksGroup,aninternationaldesign&publishingcompany.

SusanBlond– DirectorofPublicity

SusanBlondstartedhercareerpaintingwithTheWhitneyMuseumstudioprogrambutonceshegotajobatAndyWarhol’sInterview,lifewastooexcitingtopaint.Shesoldadsthereprimarilytorecordcompaniesandthemagazinetookoff.ShethenwentontoUnitedArtistsandEpic/CBSRecordswhereshebecamethefirstwomanVPinthewholeindustry.TheartistssherepresentedwereMichaelJackson,BoyGeorge,Sade,theClash,Ozzy Osbourne,CultureClub,CyndiLauper,Sade,MeatLoaf,Boston,LutherVandross,TheClashandcountlessothers.SheformedSusanBlondInc.in1986wheresherepresentedJamesBrown,Prince,DavidBowie,Usher,JulioIglesias,SpiceGirls,GeorgeJones,TheSpiceGirls,andMorrissey,andcompaniessuchasTheHardRockCafe,SportsClubLA(nowEquinox)andexecutiveslikeCharlesKoppelman andCliveDavis.SusanservesasSecretaryoftheBoardofDIFFA:DesignIndustriesFoundationFightingAIDS.

LEADERSHIPTEAM


SydneyCole- ExecutiveAssistant&OfficeManager

Ms.ColehasheldAdministrationSupportandtrainerroleswithintheHospitalityIndustryforsevenyears.Ms.ColehasalsoworkedforaVentureCapitalcompanyforfiveyearsasanexecutiveassistantandofficemanager.FrombookkeepingtoeventcoordinationMs.Cole’sorganizationandfortitudekeepoperationsrunning smoothly.

DeannaKress- DirectorofCorporateCommunications&InvestorRelations

Ms.DeannaKresshasbeeninvolvedinpubliccapitalsince2003withafocusonInvestorRelationsandCorporateCommunications.Ms.Kresshaswide-rangingexperiencewithanumberofexplorationandproductioncompanieslistedonboththeTSXVentureExchangeandtheTorontoStockExchange.Ms.Kressledvariousmarketinginitiativeswithpublicandprivatecompanymanagementteamstoassistwithequityfinancing's,tosecurecoveragefromallsectorsoftheinvestingcommunity andtoimplementinternalprocedurestoensureclearandeffectivecommunicationtostakeholders.Ms.KressholdsaMedicalDiplomaandisintheprocessofcompletingaHealthSciencesDegree.

24

LEADERSHIPTEAM


RyanVanDeventer– BusinessDevelopmentMr.VanDeventeriscurrentlyfinishinghisstudiesforComputerInformationSystems,InformationTechnologyatKwantlenPolytechnicUniversity. TrainingunderMr.VanDeventerSenior, Mr.VanDeventerjunior’sambitionsfindhimtobeaneagerfinance professional.

25

•PublicListing Advisor• Investmentbanking advisor•CEOofachemical company•COOofawireless company

• Sales&marketing•Product Development•PR& Communications•MercedesBenz finance•Dawsongroup PLC• InstituteofPublic Relations

•30+yearsBusiness Development•Business&Finance Law•Commodity Broker•Arts&Antiquities Trader•RealEstate– Prime Properties

•20yearsCorporate Strategy•575+startup consulting•Mergers& Acquisitions•BusinessDevelopmentBankof Canada• Investment Strategy

IsaacMossIsaacMossB.Sc,M.Pub.Admin.has30yearsofexperienceininternationalcorporatefinance,publicmarketsandbusiness.IsaacwasassociatedwithanadvisorygroupinGenevaSwitzerland,providingstrategicandcorporatefinanceadvisoryservicestoanumberofclientcompaniesaroundtheglobeindiverseindustriesrangingfromminingandenergy,forestproducts,technology,telecommunicationsandbiotechnology,andthehospitality industry.

RuthHenderson

Ruthhaslaunchednewproductssuccessfullyintonewandexistingmarkets,increasedprofitandmarketshareusingbothlargeandsmallbudgets– bothnationallyandinternationally– andmanagedbothinhouseandagencyworkers.Herexpertiseincludesstrategicplanning,sales,businessdevelopmentandproductdevelopment.Askilledcommunicatorandnegotiatorwithinterpersonalskillsthatincludestrongpartnerandcustomer relationships.

IanSpencer

Ianhasbeenaserialentrepreneurfromhismid20'shavingworkedinthefinanceindustryworkingasacommoditybrokerincentralLondon.IanstudiedBusinessandFinanceLawatBrunelUniversity,London,butchosecommercialtradingashispassionwasfordealingartandantiqueswhichhewasextremelysuccessfulat.

WandaHalpert

ThefounderandDirectorofConcordBusinessDevelopment,WandaHalpertisaveteraninthestrategicplanningindustry.Shehasdeliveredpresentationsontheessentialsofbusinessplanningtopubliccompanyforumsandfederallyfundedmanagementprogramsanddirectedtheproductionsofover500advancedbusinessplansindozensofindustrysectorsforbothprivateandpubliccompanies.

ADVISORYBOARD


26

PARTNERS


27

OurVision

OurVisionistobealeaderinthepreventivehealthsciencesbringinginnovativeoptionsforpreventiveandcurativetherapiesultilising organicandnatureidenticalproducts.

KeystoSuccess

Managementwithextensiveresearchexperience,productdevelopmentexperience,deepcorporatestrategyandcapitalmarketsleadership.Partneringwithleadingindustryexpertsandcompanies.

SUMMARY


28

PLEASECONTACT

StephenVanDeventerChairman&CEOCell:1(604) 306-9669Office:1(604)[email protected]

DeannaKressDirectorofCorporateCommunications&InvestorRelationsCell:1(778)999-6063Office:1(604)416– [email protected]


Documents

CSE: PREV OTCQB: PRVCF FSE: 18H - Proactiveinvestors UK€¦ · investor deck cse: prev otcqb: prvcf fse: 18h september 14, 2017